Latest Boston Scientific Corp (BSX) Headlines M
Post# of 122
Posted On: 03/13/2014 9:22:00 PM
Latest Boston Scientific Corp (BSX) Headlines
Most active New York Stock Exchange-traded stocks
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Medical Devices companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading:
Midday Glance: Medical Devices companies
AP - Thu Mar 13, 12:59PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Medical Devices companies
AP - Thu Mar 13, 9:16AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Boston Scientific passes CE Mark for REBEL Platinum Chromium Coronary Stent System to advance stent technology in CAD
M2 - Thu Mar 13, 7:02AM CDT
Medical company Boston Scientific (NYSE:BSX) revealed on Wednesday the receipt of the CE Mark approval for its latest REBEL Platinum Chromium Coronary Stent System for the treatment of coronary artery disease (CAD), a narrowing of blood vessels that supply blood and oxygen to the heart.
MediPoint: Biopsy Devices - APAC Analysis and Market Forecasts
M2 - Thu Mar 13, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wl9hj7/medipoint_biopsy) has announced the addition of the "MediPoint: Biopsy Devices - APAC Analysis and Market Forecasts" report to their offering. Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions. Countries in the Asia Pacific (APAC) region such as Japan and China and the South American country of Brazil will have growth rates that are more than double the global CAGR. This is primarily due to the increased market access of each country's population to healthcare resources and the increased adoption of more expensive core needle biopsy devices over fine needle aspiration devices. Scope - An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized APAC biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019. - Investigation of current and future market competition for biopsy devices. - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. - Analysis of unmet needs within the market and opportunities for future players. Key Topics Covered: List of Tables List of Figures Introduction Industry Overview Unmet Needs Market Opportunity Analysis Market Drivers and Barriers Competitive Assessment Pipeline Assessment Clinical Trial Analysis Current and Future Players Market Outlook Appendix Companies Mentioned Argon Medical Devices Boston Scientific Cardinal Health CareFusion Corporation Cook Medical C. R. Bard Devicor Medical Products DTR Medical Gallini Medical Devices Hologic INRAD Intact Medical Corporation TSK Laboratory For more information visit http://www.researchandmarkets.com/research/wl...int_biopsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why The ADT Corporation, Diamond Offshore Drilling Inc., and Boston Scientific Are Today's 3 Worst S
John Divine, The Motley Fool - Motley Fool - Wed Mar 12, 6:42PM CDT
Investors were decidedly undecided on Wednesday, sending 50.2% of publicly traded companies higher, relegating the other 49.8% to finish in the red or that dreaded grey zone known as purgatory. Considering the unusual balancing act Wall Street put on...
Boston Scientific Receives CE Mark Approval for REBEL(TM) Platinum Chromium Coronary Stent System
PR Newswire Europe - Wed Mar 12, 5:54PM CDT
Continuing to advance leading stent technology, Boston Scientific Corporation has received CE Mark approval for the REBEL(TM) Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).
Wake Forest University School of Business hosts 5th Annual Biotechnology Conference and Case Competition
Business Wire - Wed Mar 12, 3:00PM CDT
The Wake Forest University Biotechnology Conference and Case Competition celebrates its fifth anniversary this year. The event draws competitive teams from the nation's top schools - bringing the best and brightest minds together to solve a real issue in the biotechnology industry. For the second year, Boston Scientific serves as lead sponsor for the event March 21-22 at the Wake Forest University School of Business and Biotech Place.
Chevron Rises Despite the Dow's Struggles
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 12, 1:35PM CDT
Investors nearly had a market rout on their hands after stocks slumped in a big way to start the day, but the Dow Jones Industrial Average and other indices rebounded in the late morning and early afternoon sessions. Still, the blue-chip index was...
CR Bard Reaches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:10AM CDT
Shares of BCR started escalating following optimism triggered by promising 2014 guidance.
'Mad Money' Lightning Round: Boston Scientific Is a Favorite
at The Street - Wed Mar 12, 5:00AM CDT
Cramer also loves Occidental Petroleum but he's not recommending Bed Bath & Beyond.
Internal Beam & Systemic Radiation Therapy Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017
M2 - Wed Mar 12, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7wqw3/internal_beam_and) has announced the addition of the "Internal Beam & Systemic Radiation Therapy Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017" report to their offering. Rising cancer cases have made radiotherapy a standard procedure for oncology treatment. With a prominent rise in their GDP, emerging nations act as the future growth opportunities for the global radiotherapy market. Internal radiation therapy or brachytherapy is one of the oldest techniques for the treatment of cancerous tumors. As per the procedures, this process is categorized into permanent and temporary procedures where low dose rate and high dose rate brachytherapy are applied respectively. This report comprises of a holistic analysis of the market in terms of forces affecting the market. Its sub-components/forces include bargaining power of suppliers, bargaining power of buyers, threat of substitutes, threat of new entrants and competitive rivalry. The study analyzes the market for segments such as brachytherapy seeds, applicators and afterloaders and electronic brachytherapy along with their applications that include Prostate cancer, gynecological cancer, breast cancer, cervical cancer, penile cancer, lung cancer, head and neck cancer and esophageal cancer. The study also analyzes four regions namely, North America, Europe, Asia-Pacific and Rest of the World for the Internal Beam Radiation Devices Market. The report elucidates several dynamics of the market such as the drivers, inhibitors, and opportunities that are illustrated throughout the report. It provides current and future outlook for the market on a global level as well as a focused view on independent sub-segments within the market. The report also profiles key market players Accuray Inc., Angiodynamics Inc., Boston Scientific Corporation, C.R. Bard, Cardinal Health Inc., Covidien PLC, GE Healthcare, Siemens Healthcare, Theragenics Corporation and others. The study provides a market share analysis for the year 2012 with respect to key players and also provides recent developments for all profiled companies. Key Topics Covered - Introduction to the Report - Market Synopsis - Market Dynamics - Products Market Size & Forecast - Global Internal Beam Radiation Therapy Devices - Products Market Size & Forecast - Global Systemic Radiation Therapy Devices - Applications Market Size & Forecast - Global Internal Beam Radiation and Systemic Therapy Devices - Technology Market Size & Forecast - Global Internal Beam Radiation Therapy Devices - Geography Market Size & Forecast - Global Internal Beam & Systemic Radiation Therapy Devices - Competitive Scenario: Key Players - Company Profiles Companies Mentioned - Boston Scientific - C.R. Bard - Eckert & Ziegler BEBIG - Elekta AB - GE Healthcare - IBA - Nordion - Theragenics - Varian Medical Systems For more information visit http://www.researchandmarkets.com/research/t7...l_beam_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MediPoint: Biopsy Devices - US Analysis and Market Forecasts Research Report
M2 - Wed Mar 12, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/66ts7p/medipoint_biopsy) has announced the addition of the "MediPoint: Biopsy Devices - US Analysis and Market Forecasts" report to their offering. Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions. While the global biopsy devices market is expected to see growth over the forecast period, there are several barriers that are dampening the intervention's potential adoption levels. Notably in the US, reimbursement for image guided breast biopsies has undergone some restructuring. The 2014 Medicare Fee Schedule Final Rule imposed drastic reimbursement cuts for these procedures which will have a significant effect on the adoption of more expensive vacuum assisted biopsy (VAB) devices. Scope - An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized the US biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019. - Investigation of current and future market competition for biopsy devices - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. Companies Mentioned Argon Medical Devices Boston Scientific Cardinal Health CareFusion Corporation Cook Medical C. R. Bard Devicor Medical Products DTR Medical Gallini Medical Devices Hologic INRAD Intact Medical Corporation TSK Laboratory For more information visit http://www.researchandmarkets.com/research/66...int_biopsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Jim Cramer's 'Mad Money' Recap: Silver Lining Playbook
at The Street - Tue Mar 11, 7:04PM CDT
The markets are a healthier place today, even though most investors lost money, Cramer says.
Most active New York Stock Exchange-traded stocks
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Medical Devices companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading:
Midday Glance: Medical Devices companies
AP - Thu Mar 13, 12:59PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Medical Devices companies
AP - Thu Mar 13, 9:16AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Boston Scientific passes CE Mark for REBEL Platinum Chromium Coronary Stent System to advance stent technology in CAD
M2 - Thu Mar 13, 7:02AM CDT
Medical company Boston Scientific (NYSE:BSX) revealed on Wednesday the receipt of the CE Mark approval for its latest REBEL Platinum Chromium Coronary Stent System for the treatment of coronary artery disease (CAD), a narrowing of blood vessels that supply blood and oxygen to the heart.
MediPoint: Biopsy Devices - APAC Analysis and Market Forecasts
M2 - Thu Mar 13, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wl9hj7/medipoint_biopsy) has announced the addition of the "MediPoint: Biopsy Devices - APAC Analysis and Market Forecasts" report to their offering. Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions. Countries in the Asia Pacific (APAC) region such as Japan and China and the South American country of Brazil will have growth rates that are more than double the global CAGR. This is primarily due to the increased market access of each country's population to healthcare resources and the increased adoption of more expensive core needle biopsy devices over fine needle aspiration devices. Scope - An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized APAC biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019. - Investigation of current and future market competition for biopsy devices. - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. - Analysis of unmet needs within the market and opportunities for future players. Key Topics Covered: List of Tables List of Figures Introduction Industry Overview Unmet Needs Market Opportunity Analysis Market Drivers and Barriers Competitive Assessment Pipeline Assessment Clinical Trial Analysis Current and Future Players Market Outlook Appendix Companies Mentioned Argon Medical Devices Boston Scientific Cardinal Health CareFusion Corporation Cook Medical C. R. Bard Devicor Medical Products DTR Medical Gallini Medical Devices Hologic INRAD Intact Medical Corporation TSK Laboratory For more information visit http://www.researchandmarkets.com/research/wl...int_biopsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why The ADT Corporation, Diamond Offshore Drilling Inc., and Boston Scientific Are Today's 3 Worst S
John Divine, The Motley Fool - Motley Fool - Wed Mar 12, 6:42PM CDT
Investors were decidedly undecided on Wednesday, sending 50.2% of publicly traded companies higher, relegating the other 49.8% to finish in the red or that dreaded grey zone known as purgatory. Considering the unusual balancing act Wall Street put on...
Boston Scientific Receives CE Mark Approval for REBEL(TM) Platinum Chromium Coronary Stent System
PR Newswire Europe - Wed Mar 12, 5:54PM CDT
Continuing to advance leading stent technology, Boston Scientific Corporation has received CE Mark approval for the REBEL(TM) Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).
Wake Forest University School of Business hosts 5th Annual Biotechnology Conference and Case Competition
Business Wire - Wed Mar 12, 3:00PM CDT
The Wake Forest University Biotechnology Conference and Case Competition celebrates its fifth anniversary this year. The event draws competitive teams from the nation's top schools - bringing the best and brightest minds together to solve a real issue in the biotechnology industry. For the second year, Boston Scientific serves as lead sponsor for the event March 21-22 at the Wake Forest University School of Business and Biotech Place.
Chevron Rises Despite the Dow's Struggles
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 12, 1:35PM CDT
Investors nearly had a market rout on their hands after stocks slumped in a big way to start the day, but the Dow Jones Industrial Average and other indices rebounded in the late morning and early afternoon sessions. Still, the blue-chip index was...
CR Bard Reaches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:10AM CDT
Shares of BCR started escalating following optimism triggered by promising 2014 guidance.
'Mad Money' Lightning Round: Boston Scientific Is a Favorite
at The Street - Wed Mar 12, 5:00AM CDT
Cramer also loves Occidental Petroleum but he's not recommending Bed Bath & Beyond.
Internal Beam & Systemic Radiation Therapy Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017
M2 - Wed Mar 12, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7wqw3/internal_beam_and) has announced the addition of the "Internal Beam & Systemic Radiation Therapy Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2017" report to their offering. Rising cancer cases have made radiotherapy a standard procedure for oncology treatment. With a prominent rise in their GDP, emerging nations act as the future growth opportunities for the global radiotherapy market. Internal radiation therapy or brachytherapy is one of the oldest techniques for the treatment of cancerous tumors. As per the procedures, this process is categorized into permanent and temporary procedures where low dose rate and high dose rate brachytherapy are applied respectively. This report comprises of a holistic analysis of the market in terms of forces affecting the market. Its sub-components/forces include bargaining power of suppliers, bargaining power of buyers, threat of substitutes, threat of new entrants and competitive rivalry. The study analyzes the market for segments such as brachytherapy seeds, applicators and afterloaders and electronic brachytherapy along with their applications that include Prostate cancer, gynecological cancer, breast cancer, cervical cancer, penile cancer, lung cancer, head and neck cancer and esophageal cancer. The study also analyzes four regions namely, North America, Europe, Asia-Pacific and Rest of the World for the Internal Beam Radiation Devices Market. The report elucidates several dynamics of the market such as the drivers, inhibitors, and opportunities that are illustrated throughout the report. It provides current and future outlook for the market on a global level as well as a focused view on independent sub-segments within the market. The report also profiles key market players Accuray Inc., Angiodynamics Inc., Boston Scientific Corporation, C.R. Bard, Cardinal Health Inc., Covidien PLC, GE Healthcare, Siemens Healthcare, Theragenics Corporation and others. The study provides a market share analysis for the year 2012 with respect to key players and also provides recent developments for all profiled companies. Key Topics Covered - Introduction to the Report - Market Synopsis - Market Dynamics - Products Market Size & Forecast - Global Internal Beam Radiation Therapy Devices - Products Market Size & Forecast - Global Systemic Radiation Therapy Devices - Applications Market Size & Forecast - Global Internal Beam Radiation and Systemic Therapy Devices - Technology Market Size & Forecast - Global Internal Beam Radiation Therapy Devices - Geography Market Size & Forecast - Global Internal Beam & Systemic Radiation Therapy Devices - Competitive Scenario: Key Players - Company Profiles Companies Mentioned - Boston Scientific - C.R. Bard - Eckert & Ziegler BEBIG - Elekta AB - GE Healthcare - IBA - Nordion - Theragenics - Varian Medical Systems For more information visit http://www.researchandmarkets.com/research/t7...l_beam_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MediPoint: Biopsy Devices - US Analysis and Market Forecasts Research Report
M2 - Wed Mar 12, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/66ts7p/medipoint_biopsy) has announced the addition of the "MediPoint: Biopsy Devices - US Analysis and Market Forecasts" report to their offering. Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions. While the global biopsy devices market is expected to see growth over the forecast period, there are several barriers that are dampening the intervention's potential adoption levels. Notably in the US, reimbursement for image guided breast biopsies has undergone some restructuring. The 2014 Medicare Fee Schedule Final Rule imposed drastic reimbursement cuts for these procedures which will have a significant effect on the adoption of more expensive vacuum assisted biopsy (VAB) devices. Scope - An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized the US biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019. - Investigation of current and future market competition for biopsy devices - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. Companies Mentioned Argon Medical Devices Boston Scientific Cardinal Health CareFusion Corporation Cook Medical C. R. Bard Devicor Medical Products DTR Medical Gallini Medical Devices Hologic INRAD Intact Medical Corporation TSK Laboratory For more information visit http://www.researchandmarkets.com/research/66...int_biopsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Jim Cramer's 'Mad Money' Recap: Silver Lining Playbook
at The Street - Tue Mar 11, 7:04PM CDT
The markets are a healthier place today, even though most investors lost money, Cramer says.
(0)
(0)Boston Scientific Corporation (BSX) Stock Research Links
Scroll down for more posts ▼